IRLAB Therapeutics AB (publ) (IRLAB-A.ST)
- Previous Close
6.95 - Open
6.95 - Bid 6.74 x --
- Ask 6.86 x --
- Day's Range
6.82 - 6.95 - 52 Week Range
4.25 - 18.50 - Volume
2,283 - Avg. Volume
86,756 - Market Cap (intraday)
353.198M - Beta (5Y Monthly) 0.44
- PE Ratio (TTM)
-- - EPS (TTM)
-1.60 - Earnings Date May 7, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
21.00
IRLAB Therapeutics AB (publ) discovers and develops drugs for the treatment of Parkinson's disease and other CNS disorders. The company develops Mesdopetam that is in phase IIb clinical studies for the treatment of levodopa-induced dyskinesia; and Pirepemat, which is in phase IIb clinical trial indicated for the treatment of falls frequency, postural dysfunction, cognitive function, and symptoms of Parkinson's disease. Its preclinical stage products include IRL942 research programs for the treatment of cognitive deficits in Parkinson's and other neurological disorders; IRL757 to treat apathy in neurological diseases; and IRL1117, a drug candidate developed oral treatment for the hallmark symptoms of Parkinson's. In addition, the company develops P003, a research project that discovers and develops dopamine D1 and D2 receptor agonist compounds for the treatment of Parkinson's core motor symptoms. IRLAB Therapeutics AB (publ) was incorporated in 2013 and is headquartered in Gothenburg, Sweden.
www.irlab.seRecent News: IRLAB-A.ST
View MorePerformance Overview: IRLAB-A.ST
Trailing total returns as of 5/6/2025, which may include dividends or other distributions. Benchmark is OMX Stockholm 30 Index (^OMX) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: IRLAB-A.ST
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: IRLAB-A.ST
View MoreValuation Measures
Market Cap
360.49M
Enterprise Value
353.99M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.81
Price/Book (mrq)
11.05
Enterprise Value/Revenue
3.74
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-87.85%
Return on Assets (ttm)
-29.97%
Return on Equity (ttm)
-112.03%
Revenue (ttm)
94.63M
Net Income Avi to Common (ttm)
-83.13M
Diluted EPS (ttm)
-1.60
Balance Sheet and Cash Flow
Total Cash (mrq)
66.92M
Total Debt/Equity (mrq)
185.14%
Levered Free Cash Flow (ttm)
-44.69M